Nanjing Hicin Pharmaceutical Co., Ltd. Share Price

Equities

300584

CNE100002F44

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
16.13 CNY +0.25% Intraday chart for Nanjing Hicin Pharmaceutical Co., Ltd. +8.84% -30.71%

Financials

Sales 2022 526M 72.66M 5.82B Sales 2023 518M 71.47M 5.72B Capitalization 2.79B 386M 30.87B
Net income 2022 32M 4.42M 354M Net income 2023 36M 4.97M 398M EV / Sales 2022 7.5 x
Net Debt 2022 83.09M 11.47M 918M Net Debt 2023 224M 30.94M 2.48B EV / Sales 2023 5.83 x
P/E ratio 2022
119 x
P/E ratio 2023
76.9 x
Employees 549
Yield 2022 *
-
Yield 2023
-
Free-Float 38.61%
More Fundamentals * Assessed data
Dynamic Chart
Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. cancelled the transaction announced on June 10, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Management Changes CI
Nanjing Hicin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 400 million in funding CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022 CI
Nanjing Hicin Pharmaceutical Approves Profit Distribution for 2021 CI
Nanjing Hicin Pharmaceutical Proposes Profit Distribution for 2021 CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day+0.25%
1 week+8.84%
Current month-9.38%
1 month-9.38%
3 months-22.00%
6 months-37.43%
Current year-30.71%
More quotes
1 week
14.52
Extreme 14.52
16.43
1 month
14.20
Extreme 14.2
18.18
Current year
12.68
Extreme 12.68
23.81
1 year
12.68
Extreme 12.68
33.00
3 years
12.68
Extreme 12.68
87.40
5 years
12.68
Extreme 12.68
87.40
10 years
8.89
Extreme 8.8867
87.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 18/05/13
Director/Board Member 46 15/07/19
Investor Relations Contact - -
Members of the board TitleAgeSince
Chief Executive Officer 60 18/05/13
Director/Board Member 47 15/07/19
Director/Board Member 60 14/05/23
More insiders
Date Price Change Volume
26/04/24 16.13 +0.25% 2,639,100
25/04/24 16.09 +2.88% 2,458,500
24/04/24 15.64 +2.42% 1,619,900
23/04/24 15.27 +2.76% 1,847,001
22/04/24 14.86 +0.27% 1,628,750

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300584 Stock